Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Pooled result · Reduction in HbA1cResult — go to the resultMD −0.93 95% CI −1.36 to −0.49Authors' conclusion
In children, adolescents, and young adults with T2DM, SGLT2i appears to be effective and safe for glycemic control.
Study context
- Population
- Children, adolescents and young adults (aged 10–24 years) with T2D
- Participants
- 334 children3 studies
- Comparison
- SGLT2i vs placebo
- Outcome
- Reduction in HbA1c
Methodological detailsMean follow-up 37.79 weeks
- Mean follow-up 37.79 weeks
Pooled result
As reported in the abstract
MD
−0.93
95% CI −1.36 to −0.49
P < 0.0001
SGLT2ivs Placebo
MD −0.93 (95% CI −1.36 to −0.49); P < 0.0001
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Rescue or discontinuation of study medication due to lack of efficacyI2 = 0% | 0.64 (0.43–0.94) | P = 0.02 | |
| 0.512Relative risk (log scale) |
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Any adverse eventI2 = 0% | 1.10 (0.96–1.27) | P = 0.17 | |
| Serious side effectsI2 = 0% | 1.06 (0.44–2.57) | P = 0.90 | |
| 0.20.5125Relative risk (log scale) |
Individual adverse effects
- SGLT2i and placebo were similar in terms of individual adverse effects
Original publication
Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Pediatr Diabetes. Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →